Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REMEDY-RCC: Gut Microbiota Modulation for Immunotherapy Resensitization in Advanced Renal Cell Carcinoma - A Prospective, Exploratory, Single-Center Study

NCT07611825 is registered in ClinicalTrials.gov with Jinling Hospital, China as lead sponsor.

NCT NCT07611825
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07611825 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REMEDY-RCC: Gut Microbiota Modulation for Immunotherapy Resensitization in Advanced Renal Cell Carcinoma - A Prospective, Exploratory, Single-Center Study
Lead sponsor
Jinling Hospital, China
Phase
Phase 2
Overall status
Recruiting
Start date
June 1, 2026
Completion date
December 31, 2028
Enrollment
33 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced rcc